Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

The Breast : Official Journal of the European Society of Mastology
Onder TonyaliAnatolian Society of Medical Oncology (ASMO)

Abstract

The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab. Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively. Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER- and PR-) tumor (p = 0.001, RR: 3.4, 95% CI: 1.33-8.71) and stage 3 disease (p = 0.0032, RR: 9.39, 95% CI: 1.33-8.71) were significant risk factors for development of brain metastasis as the first site of recurrence. In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER- and PR-) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence.

References

Sep 10, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J BursteinP Klein
Sep 30, 2005·The American Journal of Pathology·Robert J WeilPatricia S Steeg
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B C PestalozziUNKNOWN International Breast Cancer Study Group (IBCSG)
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-Jones
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc SpielmannFrédérique Penault-Llorca
Nov 26, 2009·International Journal of Radiation Oncology, Biology, Physics·Anna NiwińskaMagdalena Murawska
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Jul 20, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adam M BrufskyDenise A Yardley
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRobert B Jenkins
Oct 2, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Vaz-LuisN U Lin
Mar 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E M OlsonC L Shapiro

❮ Previous
Next ❯

Citations

Feb 29, 2020·Oncotarget·Lola KonialiKyriacos Kyriacou
Aug 7, 2019·Neuro-oncology Practice·Dhiego Chaves de Almeida BastosSujit S Prabhu
Jun 9, 2018·Frontiers in Oncology·Federica FranchinoRiccardo Soffietti
Dec 15, 2020·The Breast : Official Journal of the European Society of Mastology·Yiqun LiBinghe Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.